PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome

Several cancers are highly refractory to conventional chemotherapy. The survival of tumors in several cases is assisted by checkpoint immunomodulation to maintain the imbalance between immune surveillance and cancer cell proliferation. Check point antibody inhibitors, such as anti-PD-1/PD-L1, are a...

Descripción completa

Detalles Bibliográficos
Autores principales: Alsaab, Hashem O., Sau, Samaresh, Alzhrani, Rami, Tatiparti, Katyayani, Bhise, Ketki, Kashaw, Sushil K., Iyer, Arun K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572324/
https://www.ncbi.nlm.nih.gov/pubmed/28878676
http://dx.doi.org/10.3389/fphar.2017.00561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572324/
https://www.ncbi.nlm.nih.gov/pubmed/28878676
http://dx.doi.org/10.3389/fphar.2017.00561

Ejemplares similares